SunBio,Inc. Share Price

Equities

A067370

KR7067370007

Pharmaceuticals

End-of-day quote Korea S.E. 23:00:00 18/07/2024 BST 5-day change 1st Jan Change
7,810 KRW 0.00% Intraday chart for SunBio,Inc. -0.64% -30.88%

Financials

Sales 2013 2.12B 1.53M 118M Sales 2014 2.17B 1.56M 121M Capitalization 96.18B 69.25M 5.37B
Net income 2013 648M 467K 36.17M Net income 2014 1.39B 1M 77.81M EV / Sales 2013 * -
Net cash position 2013 * - 0 0 Net cash position 2014 * - 0 0 EV / Sales 2014 * -
P/E ratio 2013 *
-
P/E ratio 2014 *
-
Employees -
Yield 2013 *
-
Yield 2014 *
-
Free-Float 66.92%
More Fundamentals * Estimated data
Dynamic Chart
SunBio,Inc. has filed an IPO. CI
SunBio,Inc. announced that it has received KRW 2 billion in funding CI
Jeong, Lee, Kim, Chang, Han and Oh acquired 3.1% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for KRW 3.3 billion. CI
Han, Kim and Oh acquired 0.91% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for approximately KRW 950 million. CI
An unknown buyer acquired 0.023% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for KRW 31.9 million. CI
An unknown individual acquired 0.56% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for approximately KRW 600 million. CI
An unknown individual acquired 0.39% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for KRW 390 million. CI
An unknown individual and others acquired 3.2% stake in SunBio,Inc. from Kangpyung Telecom Co., Ltd. for KRW 2.9 billion. CI
SunBio,Inc. has withdrawn its IPO. CI
SunBio Corporation's Equity Buyback announced on March 21, 2016 has expired. CI
Tranche Update on SunBio Corporation's Equity Buyback Plan announced on March 21, 2016. CI
SunBio Corporation announces an Equity Buyback for KRW 1,200 million worth of its shares. CI
SunBio Corporation authorizes a Buyback Plan. CI
SunBio Corporation has withdrawn its IPO. CI
SunBio Corporation cancelled the acquisition of Daewoo Special Purpose Acquisition 2 Co., Ltd. in a reverse merger transaction. CI
More news
1 week-0.64%
Current month+0.64%
1 month-1.01%
3 months-2.86%
6 months-21.90%
Current year-30.88%
More quotes
1 week
7 350.00
Extreme 7350
8 040.00
1 month
7 350.00
Extreme 7350
9 200.00
Current year
7 350.00
Extreme 7350
11 520.00
1 year
7 350.00
Extreme 7350
12 500.00
3 years
7 220.00
Extreme 7220
34 850.00
5 years
5 533.33
Extreme 5533.3333
38 900.00
10 years
5 533.33
Extreme 5533.3333
38 900.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 -
Director of Finance/CFO 69 -
Director/Board Member 67 -
Members of the board TitleAgeSince
Director/Board Member 65 31/12/18
Chief Executive Officer 66 -
Director of Finance/CFO 69 -
More insiders
Date Price Change Volume
19/07/24 7,810 0.00% 17,347
18/07/24 7,810 -2.25% 22,786
17/07/24 7,990 +1.65% 16,657
16/07/24 7,860 +0.77% 23,321
15/07/24 7,800 -0.76% 26,427

End-of-day quote Korea S.E., July 18, 2024

More quotes
SunBio,Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. The Company operates its business through three segments. The Polyethylene Glycol (PEG) Derivative Product business segment is involved in the manufacturing and sale of PEG derivative products. The PEG derivatives are intermediate materials used in dermal filler, drug delivery systems, hydrogel, and nanotechnology. The Biosimilar Business segment is involved in the manufacturing and sale of royalty and technology transfer products. The main products are neutropenia treatment products, and hepatitis C treatment products. The New Drug Development Business segment is involved in the development of oxygen carriers, artificial blood, stroke aid agents, cartilage synovial fillers, dry mouth treatment drugs, and long-term preservatives.
More about the company
  1. Stock Market
  2. Equities
  3. A067370 Stock